Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS
Benzinga Newsdesk 4 months ago
News
Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical developmentTibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline
- Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development
- TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026
- TibuSURE has exceeded the 80 participant enrollment target in SSc and remains on track to complete enrollment in early July; topline data expected H1 2027
- Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026